Skip over navigation
Banner
Industry
Directory Facilities Technology Transfer Economic Develop. KS BioHistory (TM)
Career
Job Search Post a Job Submit Resume Destination KS
News/Events
Local KS News Submit News Release Calendar Submit Event CEO Reading
Patient
Clinical Trials Local Support National Resources
Education
K-12 Higher Ed BioEd Reading
About
Advertising Feedback Home
 
About
 Advertising
 Feedback
 Home
Quick Links
 Directory
 Job Search
 Facilities
 Calendar
 Advertising
Community Service Ad: CDC Get Vaccinated
Advertising
 
Jobs
 

NEW University of Washington Basic Bioscience Certificate starts Jan 2009

UW M.S. in Biomedical Regulatory Affairs with evening classes for working professionals


Medchem Source

Local News

Submit News Release


Search Articles: 

  • Monsanto Company completes acquisitions of CanaVialis and Alellyx  Monsanto announced that it has completed its proposed acquisition of Aly Participacoes, which operates the sugarcane breeding and technology companies, CanaVialis and Alellyx, both of which are based in Brazil.
    Monsanto Company December 02, 2008  
  • Monsanto to leverage its technology to enhance yield and economic value for farmers  As farmers in the U.S. are making their initial seed purchase decisions for the 2009 growing season, Monsanto Company plans to discuss the reasons behind its confidence that it can make good on its commitment to more than double its fiscal 2007 gross profit by 2012.
    Monsanto Company December 02, 2008  
  • GSK and Theravance announce positive phase 2b results for LABA, `444  GlaxoSmithKline and Theravance announced positive results from the phase 2b study of the novel, long-acting beta agonist (LABA) GW642444 (‘444) in patients with moderate to severe asthma.
    GlaxoSmithKline December 02, 2008  
  • ETHICON completes divestiture of Professional Wound Care Business to One Equity Partners  ETHICON, a Johnson & Johnson company, announced that it has completed the divestiture of its Professional Wound Care business to One Equity Partners. Financial terms of the transaction are not being disclosed.
    Johnson & Johnson December 01, 2008  
  • Suvica promises to enhance drug discovery on the backs of fruit flies  Irradiating mutant flies may sound like a decent premise for a new sci-fi movie, but Dr. Tin Tin Su is looking to put this approach to a more practical and potentially profitable use – the initial screening of cancer drugs.
    Rocky Radar December 01, 2008  
  • Nuvelo and ARCA biopharma advance toward completion of merger  Nuvelo and ARCA biopharma announced that a special meeting of Nuvelo's stockholders will take place Wednesday, January 7. The purpose of the special meeting is, among other matters, to approve the actions necessary to consummate the merger between the two companies announced on September 25, 2008.
    Nuvelo, Inc. December 01, 2008  
  • Johnson & Johnson announces definitive agreement to acquire Mentor  Johnson & Johnson and Mentor Corporation, a leading supplier of medical products for the global aesthetic market, announced a definitive agreement whereby Mentor will be acquired for approximately $1.07 billion in a cash tender offer.
    Johnson & Johnson December 01, 2008  
  • Lilly withdraws application for additional U.S. indication for Cymbalta for chronic pain  Eli Lilly and Company has withdrawn its supplemental New Drug Application (sNDA) from the U.S. Food and Drug Administration (FDA) for Cymbalta(R) (duloxetine HCl) for the management of chronic pain.
    Eli Lilly and Company November 28, 2008  
  • MedImmune receives FDA Complete Response letter on motavizumab  AstraZeneca announced that MedImmune, its wholly owned biologics business, has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) asking for additional information on motavizumab.
    AstraZeneca November 28, 2008  
  • Wyeth and Progenics announce positive outcome of Phase 3 study of subcutaneous RELISTOR  Wyeth Pharmaceuticals and Progenics Pharmaceuticals announced that a phase 3 clinical study investigating RELISTOR(R) subcutaneous injection to treat opioid-induced constipation (OIC) in patients with chronic, non-cancer pain achieved statistical significance for the primary endpoints.
    Progenics Pharmaceuticals, Inc. November 26, 2008  

   (next 10 articles)

Search Articles: 


Submit News Release

 
Email thie page to a friend. Email This Page
to a Friend
Print this page. Print This
Page

© 2008 Info.Resource, Inc. All rights reserved.
Privacy Policy . Terms of Use . Advisory Board . Advertising

KansasLifeScience.com, owned and published by Info.Resource, Inc., is a resource
for the life science industry in the state of Kansas.